Development of a live attenuated varicella vaccine

Biken J. 1975 Mar;18(1):25-33.

Abstract

The Oka strain of varicella virus, isolated in our labolatory, was serially cultivated in guinea-pig embryo cultures (GPEC), and a considerable amount of cell-free virus was obtained from infected cell. GPEC passage virus at the 6th passage level was used in a small scale field trial. Susceptible children of 1 to 10 years old were injected subcutaneously with 100 to 1,000 PFU of virus. No clinical reactions due to the vaccination were observed in any children, and a high rate of antibody response was obtained with viral doses of more than 200 PFU. Attenuated virus obtained by passage in GPEC was propagated in human diploid (WI-38) cells, and it was also effective in inducing an immune response without clinical reactions. The results show that the Oka strain of varicella virus passaged in GPEC and human diploid (WI-38) cells may be used safely and effectively as a live attenuated vaccine.

MeSH terms

  • Animals
  • Antibodies, Viral / analysis
  • Antibody Formation
  • Cells, Cultured
  • Child
  • Child, Preschool
  • Complement Fixation Tests
  • Diploidy
  • Embryo, Mammalian
  • Female
  • Fluorescent Antibody Technique
  • Guinea Pigs
  • Herpesvirus 3, Human / immunology*
  • Herpesvirus 3, Human / pathogenicity
  • Humans
  • Infant
  • Injections, Subcutaneous
  • Lung
  • Male
  • Methods
  • Neutralization Tests
  • Vaccination
  • Vaccines, Attenuated*
  • Viral Vaccines*
  • Virulence

Substances

  • Antibodies, Viral
  • Vaccines, Attenuated
  • Viral Vaccines